The Dose-Response of Inhaled Corticosteroids in Combination Inhaled Corticosteroid/Long Acting Beta2-Agonist Maintenance Therapy for Asthma
CHEST · 2025-12 · 168 (6) · 1304-1316
DOI: 10.1016/j.chest.2025.08.014 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift CHEST, 2025-12. Verfasst von Jonathan H Noble und 7 weiteren Autor:innen. Beteiligte Einrichtung: Medical Research Institute of New Zealand, Wellington, New Zealand; School of Biological Sciences, Victoria University of Wellington, Wellington, New…. Hauptthemen laut MEDLINE: Asthma, Adrenal Cortex Hormones, Adrenergic beta-2 Receptor Agonists, Anti-Asthmatic Agents. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Health Research Council of New Zealand.
Abstract (Originalsprache)
BACKGROUND: High doses of a maintenance inhaled corticosteroids (ICSs) in asthma may achieve only modest additional clinical benefit beyond low-to-medium doses and are associated with an increased risk of adverse systemic effects. The ICS dose-response relationship when administered as maintenance combination ICS/long-acting beta2-agonist (LABA) therapy is uncertain. RESEARCH QUESTION: What is the ICS dose-response of maintenance ICS/LABA therapy? STUDY DESIGN AND METHODS: A systematic review was conducted using MEDLINE, Embase, the Cochrane Register of Controlled Trials, and ClinicalTrials.gov databases to identify randomized controlled trials that allocated participants to > 1 ICS dose category, per Global Initiative for Asthma categorization, administered in combination with ICS/LABA inhalers. Meta-analysis compared outcomes of high-dose (HD) and medium-dose (MD), HD and low-dose (LD), and MD and LD ICS/LABA. The primary outcome was the proportion of participants with ≥ 1 severe asthma exacerbation; secondary outcomes were patient-reported outcome measures of asthma control, spirometry, and serious adverse events. Certainty of evidence was assessed by using the Grading of Recommendations, Assessment, Development and Evaluations domains. RESULTS: Twelve randomized controlled trials (6,373 participants) were identified: 7 comparing HD vs MD ICS/LABA, 1 HD vs LD ICS/LABA, and 4 MD vs LD ICS/LABA. HD vs MD ICS/LABA reduced the odds of a severe asthma exacerbation (Peto's OR, 0.81; 95% CI, 0.67-0.98) with high certainty. There were no other clinically important differences in efficacy or safety outcomes of HD vs MD ICS/LABA. There was no difference in all outcomes comparing HD with LD or MD with LD ICS/LABA. INTERPRETATION: Our results showed that maintenance HD ICS/LABA reduced the odds of a severe exacerbation by about 20% compared with MD ICS/LABA. The absolute reduction in severe exacerbation risk with HD ICS/LABA is determined by patients' exacerbation risk, and this effect size may be clinically relevant for patients if this risk is high. Comparisons of other doses of ICS/LABA were limited by the number of identified studies, although no large difference in effect sizes were observed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Research Institute of New Zealand, Wellington, New Zealand; School of Biological Sciences, Victoria University of Wellington, Wellington, New Zealand. Electronic address: jon.noble@mrinz.ac.nz.
- Medical Research Institute of New Zealand, Wellington, New Zealand.
- University of Otago, Wellington, New Zealand.
- Medical Research Institute of New Zealand, Wellington, New Zealand; School of Biological Sciences, Victoria University of Wellington, Wellington, New Zealand.
Förderung
- Health Research Council of New Zealand
Zitieren
APA
Noble, J. H., Warhurst, S., Cullen, R., Sayers, R., Lynch, F., Kulathinal, J., Weatherall, M., & Beasley, R. W. (2025). The Dose-Response of Inhaled Corticosteroids in Combination Inhaled Corticosteroid/Long Acting Beta2-Agonist Maintenance Therapy for Asthma. CHEST, 168(6), 1304-1316. https://doi.org/10.1016/j.chest.2025.08.014
Vancouver
Noble JH, Warhurst S, Cullen R, Sayers R, Lynch F, Kulathinal J, et al. The Dose-Response of Inhaled Corticosteroids in Combination Inhaled Corticosteroid/Long Acting Beta2-Agonist Maintenance Therapy for Asthma. CHEST. 2025;168(6):1304-1316. doi:10.1016/j.chest.2025.08.014
BibTeX
@article{Noble2025,
author = {Noble, Jonathan H and Warhurst, Samantha and Cullen, Ryan and Sayers, Ross and Lynch, Francesca and Kulathinal, Joseph and Weatherall, Mark and Beasley, Richard W},
title = {The Dose-Response of Inhaled Corticosteroids in Combination Inhaled Corticosteroid/Long Acting Beta2-Agonist Maintenance Therapy for Asthma},
journal = {CHEST},
year = {2025},
volume = {168},
number = {6},
pages = {1304--1316},
doi = {10.1016/j.chest.2025.08.014}
}
EUVIMED